Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care
# Background Rivaroxaban, a fixed-dose oral direct factor Xa inhibitor, does not require continuous monitoring and thus reduces the hospital stay and economic burden in low-risk pulmonary embolism (LRPE) patients. # Study Question What is the effectiveness of rivaroxaban versus the standard of ca...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Columbia Data Analytics, LLC
2019-10-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Acceso en liña: | https://doi.org/10.36469/9936 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|